ABSTRACT
We present an operant system for the detection of pain in awake, conscious rodents. The Orofacial Pain Assessment Device (OPAD) assesses pain behaviors in a more clinically relevant way by not relying on reflex-based measures of nociception. Food fasted, hairless (or shaved) rodents are placed into a Plexiglas chamber which has two Peltier-based thermodes that can be programmed to any temperature between 7 °C and 60 °C. The rodent is trained to make contact with these in order to access a reward bottle. During a session, a number of behavioral pain outcomes are automatically recorded and saved. These measures include the number of reward bottle activations (licks) and facial contact stimuli (face contacts), but custom measures like the lick/face ratio (total number of licks per session/total number of contacts) can also be created. The stimulus temperature can be set to a single temperature or multiple temperatures within a session. The OPAD is a high-throughput, easy to use operant assay which will lead to better translation of pain research in the future as it includes cortical input instead of relying on spinal reflex-based nociceptive assays.
Subject(s)
Conditioning, Operant , Facial Pain/physiopathology , Nociceptive Pain/physiopathology , Pain Measurement/instrumentation , Pain Measurement/methods , Animals , Male , Mice , Rats , Rats, Sprague-DawleyABSTRACT
Analgesia is particularly susceptible to placebo responses. Recent studies in humans have provided important insights into the neurobiology underlying placebo-induced analgesia. However, human studies provide incomplete mechanistic explanations of placebo analgesia because of limited capacity to use cellular, molecular, and genetic manipulations. To address this shortcoming, this article describes the development of a rat model of conditioned analgesia in an operant pain assay. Specifically, rats were conditioned to associate a placebo manipulation with the analgesic effect of 1mg/kg morphine (subcutaneously) on facial thermal pain. We found that conditioned (placebo) responding bore 3 of the hallmarks of placebo-induced analgesia: (1) strong interanimal variability in the response, (2) suppression by the opiate antagonist naloxone (5mg/kg subcutaneously), and (3) a positive predictive relationship between the unconditioned analgesic effect and the conditioned (placebo) effect. Because of the operant nature of the assay and the use of only a mild noxious thermal stimulus, we suggest that these results provide evidence of placebo-induced analgesia in a preclinical model that utilizes an affective behavioral end point. This finding may provide opportunities for invasive preclinical studies allowing greater understanding of placebo-induced analgesia, thus paving the way for avenues to harness its benefits.
Subject(s)
Analgesics, Opioid/therapeutic use , Conditioning, Operant , Disease Models, Animal , Morphine/therapeutic use , Pain/diagnosis , Pain/drug therapy , Placebo Effect , Animals , Humans , Male , Rats , Rats, Hairless , Rats, Sprague-Dawley , Treatment OutcomeABSTRACT
Sweet solutions are commonly used in animal research to deliver drugs to test for addictive capacity and efficacy. In this study we compared the effects of a range of sucrose and saccharin concentrations on the performance of an operant assay. Our findings demonstrate that across a range of sucrose solutions some produce a success ratio which could mistakenly be labeled allodynic demonstrating the importance of choosing the correct reward solution.
Subject(s)
Conditioning, Operant/drug effects , Hyperalgesia/chemically induced , Pain Threshold/drug effects , Reward , Sweetening Agents/pharmacology , Analysis of Variance , Animals , Dose-Response Relationship, Drug , Hot Temperature , Male , Nutritive Value , Pain Threshold/physiology , Rats , Rats, Hairless , Rats, Sprague-Dawley , Saccharin/pharmacology , Statistics, Nonparametric , Sucrose/pharmacology , Thermosensing/drug effectsABSTRACT
Mechanical pain sensitivity is characteristic of many orofacial pain conditions; however, few models exist to quantify this pain. Here we evaluated a novel adaptation of our existing operant system to characterize orofacial pain following mechanical and thermal stimuli. We demonstrate that the operant system is able to detect painful and analgesic responses to mechanical stimuli. These findings allow comparison of both mechanical and thermal stimuli using the same outcome measures.
Subject(s)
Adaptation, Physiological/physiology , Facial Pain/physiopathology , Hyperalgesia/physiopathology , Analysis of Variance , Animals , Capsaicin/adverse effects , Conditioning, Operant/physiology , Disease Models, Animal , Hyperalgesia/chemically induced , Male , Pain Measurement/methods , Pain Threshold/physiology , Rats , Rats, Sprague-DawleyABSTRACT
UNLABELLED: Individuals with chronic craniofacial pain experience symptoms that are consistent with central sensitization. In fact, central sensitization may constitute the major disease process in these conditions, particularly if the original injury has healed or the condition is idiopathic. To understand central sensitization we have developed a conjugate of substance P and cholera toxin (SP-CTA). SP-CTA is selectively taken up by cells that express neurokinin receptors. Twenty-four hours following intracisternal administration of SP-CTA, wild-type rats and mice demonstrated signs of persistent background nociception, but when tested for facial cold sensitivity, they did not differ from controls. However, treating the SP-CTA-injected animals with naloxone exposed cold hypersensitivity in the face. Mu-opioid receptor knockout mice treated with SP-CTA demonstrated hypersensitivity without naloxone treatment. These findings suggest that central sensitization leads to activation of an endogenous opioid system. The data also demonstrate that the intracisternal administration of SP-CTA in rodents is a useful model for studying central sensitization as a disease process without having to induce a peripheral injury. PERSPECTIVE: Central sensitization is a concern in many craniofacial pain conditions. In this project, we utilize a conjugate of substance P and the catalytic subunit of cholera toxin to induce central sensitization in the nucleus caudalis of rodents. The data indicate that the injected animals become hypersensitive in the face.
Subject(s)
Cholera Toxin/pharmacology , Substance P/pharmacology , Trigeminal Caudal Nucleus/drug effects , Animals , Behavior, Animal/drug effects , Blotting, Western , Cholera Toxin/therapeutic use , Cisterna Magna , Conditioning, Operant/drug effects , Dose-Response Relationship, Drug , Facial Pain/drug therapy , Female , Immunohistochemistry , Injections , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Pain Measurement , Rats , Rats, Hairless , Rats, Sprague-Dawley , Receptors, Opioid, mu/genetics , Receptors, Opioid, mu/physiology , Substance P/therapeutic useABSTRACT
The role of tumor necrosis factor-alpha (TNF-alpha) after spinal cord injury (SCI) is well characterized in the cord, but the impact of this inflammatory process on supraspinal levels is unknown. This study examines TNF-alpha mRNA and protein levels in the brains and spinal cords of mice after SCI. Mice received intraspinal injections of quisqualic acid (QUIS) to create an excitotoxic injury that is known to result in pain behaviors. An ELISA determined serum levels of TNF-alpha, whereas real-time PCR and Western blot analysis were used to determine mRNA and protein levels, respectively, at 3, 6, 12, 24, 48, 72 h, or 14 d postinjury. No difference existed in serum TNF-alpha levels between sham- and QUIS-injected animals. TNF-alpha mRNA in the cord was increased at 3, 6, 12, and 24 h in QUIS-injected animals relative to shams. TNF-alpha protein was elevated at 12 and 48 h postinjury. TNF-alpha mRNA levels in the brain were elevated at 12 and 24 h, with elevated protein levels at 6 h. Animals that developed pain behaviors had increased levels of TNF-alpha mRNA in the brain. Excitotoxic SCI results in altered TNF-alpha mRNA and protein levels in the cords and brains of mice within 6 h of injury. These changes likely contribute to the pathogenesis of injury within the cord. The role of TNF-alpha in the brain postinjury has not been defined but might contribute to the development of pain post-SCI.